Xenetic Biosciences, Inc. (XBIO)
XBIO moved a median of 0.00% 30 minutes after news, and +0.94% by the close. How XBIO actually reacts to news — the realized, point-in-time move the market made, measured across 121 labeled events over the last three years with zero look-ahead.
XBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 25% | 89 |
| 30-min | 0.00% | 38% | 100 |
| 60-min | 0.00% | 46% | 109 |
| to close | +0.94% | 53% | 118 |
| Middle 50% of XBIO reactions | -1.15% to +1.73% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 121 |
Half of all Xenetic Biosciences, Inc. news events land between -1.15% and +1.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when XBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XBIO's baseline. Nothing else.
Recent XBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma | Press release | ACCESS Newswire | -0.24% | -3.83% | |
| Form 8-K Xenetic Biosciences, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -0.78% | -3.52% | |
| Form 8-K Xenetic Biosciences, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -9.82% | -20.36% | |
| Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics | Press release | ACCESS Newswire | -9.82% | -20.36% | |
| Form 8-K Xenetic Biosciences, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +10.45% | |
| Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform | Press release | ACCESS Newswire | +0.35% | +10.45% | |
| Form 10-Q Xenetic Biosciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.35% | +10.45% | |
| Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma | Press release | ACCESS Newswire | +0.90% | +2.69% | |
| Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival | Press release | ACCESS Newswire | -0.94% | +4.09% | |
| Form 8-K Xenetic Biosciences, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +5.93% | +7.80% | |
| Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform | Press release | ACCESS Newswire | +5.93% | +7.80% | |
| Form 10-Q Xenetic Biosciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.93% | +7.80% | |
| Form 10-K/A Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -6.48% | |
| Form 8-K Xenetic Biosciences, For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.48% | |
| Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting | Press release | ACCESS Newswire | +0.31% | -1.88% | |
| Form 8-K Xenetic Biosciences, For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | -3.36% | -2.85% | |
| Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results | Press release | ACCESS Newswire | -3.36% | -2.85% | |
| Form 10-K Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.36% | -2.85% | |
| Form 8-K Xenetic Biosciences, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | — | +5.32% | |
| Form 8-K Xenetic Biosciences, For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | — | +1.25% | |
| Form DEFA14A Xenetic Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | — | +1.25% | |
| Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting | Press release | ACCESS Newswire | — | +1.25% | |
| Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform | Press release | ACCESS Newswire | +4.30% | +1.60% | |
| Form 8-K Xenetic Biosciences, For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results | Press release | ACCESS Newswire | +0.00% | — | |
| Form 10-Q Xenetic Biosciences, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form ARS Xenetic Biosciences, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -5.46% | |
| Form DEF 14A Xenetic Biosciences, For: Dec 11 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -5.46% | |
| Form DEFA14A Xenetic Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -5.46% | |
| Form 8-K Xenetic Biosciences, For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -1.82% | -3.06% | |
| Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock | Press release | ACCESS Newswire | -5.65% | -25.44% | |
| Form 8-K Xenetic Biosciences, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +4.69% | +7.94% | |
| Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results | Press release | ACCESS Newswire | +4.69% | +7.94% | |
| Form 10-Q Xenetic Biosciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.69% | +7.94% | |
| Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma | Press release | ACCESS Newswire | -0.32% | -3.54% | |
| Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform | Press release | ACCESS Newswire | +0.00% | +0.28% | |
| Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C | Press release | ACCESS Newswire | +0.00% | +5.64% | |
| Form 8-K Xenetic Biosciences, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | — | +2.29% | |
| Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | ACCESS Newswire | — | +2.29% | |
| Form 10-K/A Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +2.29% | |
| Form 10-Q Xenetic Biosciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +2.29% | |
| Form 10-K/A Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | -0.35% | |
| Form 8-K Xenetic Biosciences, For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.65% | |
| Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment | Press release | ACCESS Newswire | +0.00% | +4.76% | |
| Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma | Press release | ACCESS Newswire | -0.88% | -3.25% | |
| Form 8-K Xenetic Biosciences, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.04% | |
| Form 8-K/A Xenetic Biosciences, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | — | -1.29% | |
| Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results | Press release | ACCESS Newswire | +0.00% | +3.04% | |
| Form 10-K Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +3.04% | |
| Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses | Press release | ACCESS Newswire | -4.62% | -7.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XBIO section they belong to.
Where else XBIO is measured.
XBIO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| American Shared Hospital Services (AMS) | 121 | 0.00% | 48% |
| Protagenic Therapeutics, Inc. (PTIX) | 121 | 0.00% | 39% |
| Avenue Therapeutics, Inc. (ATXI) | 120 | 0.00% | 37% |
| CARL ZEISS MEDI UNSP/ADR (CZMWY) | 120 | -0.21% | 21% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Xenetic Biosciences, Inc.'s median reaction calculated?
Every labeled XBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 121 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of XBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.